The RTP Gold Rush: 10 FedNow Predictions

Originally published in Forbes

The United States’ long-awaited real-time payments (RTP) system, FedNow, is due to launch any day now. The availability of instant money transfers has huge potential to impact virtually all players in the economy, from financial institutions and corporate giants to online shoppers, small business owners and employees.

In her second story as a Forbes contributor, Rocio Wu draws parallels between US payments infrastructure and the rest of the world, where centralized RTP infrastructure has been up and running for some time now. The result is ten predictions about how the payments landscape will change now that FedNow is live.

Read the full story here.

ARTBIO: Redefining cancer care through an entirely new class of alpha radioligand therapies (ARTs)

There is a need for better isotopes to make ARTs that will enable transformative efficacy and a stable treatment supply for reliably reaching patients.

 

ARTBIO is developing ARTs that have the potential to unlock a new generation of more effective and safer precision oncology medicines.

Radiopharmaceutical Landscape: Seeking a best-in-class isotope

Radioligand therapies are a category of innovative targeted cancer medicines. These drugs home specifically to tumors to deliver a potent radioactive isotope warhead, causing catastrophic DNA damage and cancer cell death. While the radioligand landscape is currently dominated by beta-emitting isotopes, the alpha emitters comprising ARTs are expected to offer a superior therapeutic index, because they can directly cause double-strand DNA breaks, which are lethal to cancer cells, and, due to a shorter emission distance, alphas can kill tumor cells locally while sparing nearby healthy tissue.

Early clinical data with a warhead called actinium-225 (Ac-225) supports the potential for ARTs to be more effective than beta emitters. However, the supply of Ac-225 has been limited creating a challenge for deploying ARTs at scale. Ac-225 also has a relatively long half-life, facilitating distribution but potentially limiting maximal therapeutic efficacy. There is a need for better isotopes to make ARTs that will enable transformative efficacy and a stable treatment supply for reliably reaching patients.

Read the Frontiers in Medicine article ‘Commercial and business aspects of alpha radioligand therapeutics’ to learn more about the research conducted on targeted alpha particle therapy in oncology.

The Origin Story: Capitalizing on a foundational discovery

In observing the many complexities in the field (including recent supply chain challenges faced by pharma), F-Prime Partner Alex Pasteur, Ph.D., and Senior Associate, Martin Taylor, Ph.D., searched for a viable solution that would fully unlock the tremendous potential of ARTs. They established relationships with world-leading experts Roy Larsen, Ph.D., and Øyvind Bruland, MD, based in Oslo, Norway, and became interested in an innovative approach they were developing for ARTs.

“ARTBIO’s roots trace back to a remarkable scientific discovery of the 20th century by Marie Curie that radium can destroy tumors, and the early dissemination of that discovery to Norway,” said Alex Pasteur. “We have tapped into long-established expertise at the Radium Hospital in Oslo for some of the foundational technology in ARTBIO.”

Roy and Øyvind are serial entrepreneurs in the radiopharmaceuticals field. They previously co-founded Algeta (acquired by Bayer) and invented Xofigo®, a drug for prostate cancer patients based on radium and currently the only alpha-emitter based medicine on the market. Alongside other companies they founded, their expertise and success has established Oslo as a hub for innovation in radiopharmaceuticals.

“F-Prime’s global presence, including our office in London, enabled us to identify radiopharmaceuticals as an area of excellence in Europe, where we saw a thriving ecosystem with an exceptional degree of innovation, ripe for further investment,” said Martin Taylor.

Why We Invested: ARTBIO’s mission to unlock the full therapeutic potential of ARTs with an optimized warhead platform

Roy and Øyvind had an intriguing idea, derived from their experience with radium. Recognizing the clinical and commercial importance of isotope choice and abundance, they turned to lead-212 (Pb-212), a decay product of radium.

Pb-212 solves many of the challenges of ARTs:

  •  It has an abundant raw material supply from existing stockpiles which avoids the expensive supply chains of other isotopes by recycling natural -byproducts of other industries.
  •  It has a short half-life, enabling maximal radiation exposure in tumors, while sparing healthy tissue and reducing post-treatment patient isolation time.
  •  It also has limited industrial competition, and can be directly imaged using existing medical systems.

Working closely with the founders and Anders Tuv from Radforsk, a local investor affiliated with the Radium Hospital who also played a key role in establishing the company’s Norwegian operations, F-Prime led an effort to design and develop a robust Pb-212 manufacturing technology platform. ARTBIO was born.

“The true value that ARTBIO brings to the ART landscape lies in aligning radionuclide half-life to drug half-life, rather than aligning radionuclide half-life to centralized manufacturing constraints,” said Emanuele Ostuni, CEO of ARTBIO. “This mindset has allowed us to choose what we believe to be the most patient-centric isotope available for clinical applications. F-Prime has been an exceptional partner on this journey, with a sleeves-rolled-up approach to company building which has significantly enabled ARTBIO’s trajectory.”

Our Focus on Company Creations: The art of curating a smarter strategy, at every turn

At F-Prime, it’s our privilege to invest in high-conviction entrepreneurs such as Emanuele, Roy, and Øyvind. We focus our energy on early company incubation, financing expertise, and industry relationships to help establish our companies on a strong trajectory.

At ARTBIO’s earliest stage, we were pleased to provide operational support including:

Talent:

    • Hiring team: Backing a world-class team is central to F-Prime’s approach. We helped to recruit cancer industry veteran Emanuele Ostuni from Novartis to be CEO. We value Emanuele’s background in managing complex deployments of CAR-T cell therapies and his strong drive to develop new drugs for cancer patients. In parallel, F-Prime helped to onboard several key early hires, spanning clinical development operations, productization of the Pb-212 manufacturing technology, and BD and portfolio strategy.
    • SAB: F-Prime assembled the company’s world-class scientific advisory board. The team helped to organize an inaugural SAB meeting and a radiopharmaceuticals workshop in 2022, bringing together key opinion leaders to help define ARTBIO’s drug discovery pipeline build strategy.

Research & Development:

    • Pb-212 Manufacturing: F-Prime helped to establish early manufacturing capability that was essential for initiating ARTBIO’s first clinical trial in Norway in early 2023.
    • Target prioritization: The SAB and workshop meetings evolved into a collaborative target prioritization working group led by F-Prime, ARTBIO team members, and the SAB and leading to the initiation of several drug discovery campaigns in the pipeline.

Distribution:

    • Strategy: F-Prime provided active early support to build a production and distribution ecosystem, with embedded redundancy and flexibility. We forged strategic partnerships to create a network of manufacturing sites, as opposed to a centralized facility with a risk of single-point failure. F-Prime identified multiple sources of radioisotope raw materials to ensure a plentiful Pb-212 supply.

We were excited to announce the launch of ARTBIO on 21 June 2023 with a $23 million seed financing alongside our co-investor Omega Funds.

Read the press release for more information on the financing.

Key Takeaways from Robotics Invest 2023

Sanjay Aggarwal reflects on our inaugural Robotics Invest summit

Co-authored with Fady Saad of Cybernetix Ventures

The ideas outlined below come from the panelists, as summarized by our team taking notes on the day. To stay in touch, follow Robotics invest on LinkedIn and Twitter

Last week, we welcomed some of the robotics industry’s leading entrepreneurs, investors, and operators to Boston for Robotics Invest, an invite-only summit packed with keynotes, panels, case studies, and robot demos.

We were very intentional in curating the speakers in these panels and, judging from the overwhelming response in the room, these discussions delivered. We’re extremely grateful to all our panelists for sharing their wisdom and experience with the group.

While the event itself was oversubscribed, we wanted to make sure everyone had the chance to access the insight, experience, and tactical advice that was available throughout the day. Luckily, our team was on hand to take notes. Here, we’ve summarized the key takeaways from each Robotics Invest panel conversation.

 

Robotics as an Investment Class

robotics as an asset class

– Robotics sits in between two ends of the spectrum in the investing community: SaaS and biotech. This means that investors might look at robotics companies with a lens that may not fit, and try to optimize for metrics or markers for success that aren’t relevant for this category.

– Likewise, robotics companies often don’t follow the typical growth trend of your average SaaS business. For example, Kiva Systems spent three-to-four years with flat growth before it really took off.

– We are still in the early days of robotics investment, especially when compared to the SaaS sector. The labor shortage is a secular issue, and the economy requires automation to keep up GDP growth.

– A solution’s lifetime value is an important metric in robotics, after factoring in capital and operational costs. Only looking at year-by-year margins may tell the wrong story.

– We are starting to see an evolution in financing models, which includes availability of equipment financing, which is helping to mitigate the capital costs of hardware.

– Revenue benchmarks aren’t as important for robotics companies at the Series A stage, nor is LTV/CAC. Instead, investors are looking for evidence that customers are moving beyond initial pilots and deploying the systems in production and at scale.

 

Building Product, Manufacturing & Supply Chain Strategies for Scale

building robotics companies for scale

– To succeed, robotics companies need to build great applications at the right time. For example, companies had tried to build cleaning robots in the 1990’s but the timing wasn’t right. And while matching macro conditions to the tech and value proposition is key, robotics companies should not let perfection trump a solution that’s “good enough.”

– Your first two hires should be a subject matter expert who can build the technology, and a subject matter expert who deeply understands the problem. Your first sales hire should be able to roll with the inevitable bugs and customer success issues, and be willing to go on this journey with you.

– Understand your technology’s core competency and be able to do that in-house. Everything else is an opportunity to outsource. However, you need to be careful about which tier of contract manufacturer you go with — if you don’t have a level of mind share with them, it can be hard to maintain the quality of your end product.

– Identify what’s essential and build it — over-engineering solutions is a common issue that can lead to cost escalation. It’s easier to add a feature in the future than take it away to reduce costs.

– There are a number of advantages to a Robotics-as-a-Service model. Reducing the capital intensity of an up-front sale can accelerate deployment, and you get a lot more customer engagement through the RaaS model. When a customer is evaluating your service’s value on a regular basis, you get a certain baseline of customer engagement.

 

Building a GTM Strategy for Scale

go to market strategy robotics

– Robotics startups should be talking to and incorporating the feedback of customers on day one. The transition to asking for payment can be tough and industry dependent — for example, contractors tend to pay their subcontractors when the job is done, and will not pay up front — so a pilot is usually necessary.

– Sales tend to fall apart when startups overpromise. Your timing needs to be realistic, and you must provide support over the longer term.

– The systems integrators flywheel can take a while to get going, and it’s not right for every use case. Startups at the very early stage should work directly with customers for design iteration. When you’re ready to deploy 10-99 units, a smaller system integrator (SI) can help customize the solution. And when you’re selling 100+, you’re ready for a larger SI like Dematic, Schaefer, or Honeywell.

– Lock-in long lead times on your supply chain early, and then design around them. You also need to be flexible and creative on how you source — for example, second-hand markets can be invaluable. As a general rule, designing around your supply chain up front can solve a lot of problems.

– Not all growth is good growth. The number one thing autonomous mobile robotics companies should work towards is a high number of customer relationships, and how you can expand the profitability for each. In other words, land-and-expand is critical.

 

Raising Money from Later Stage Investors

– The later stage is less aspirational than the early stage. The early stage is about selling the sizzle — the later stage is about selling the steak.

– Valuation matters, but it’s more important to focus on getting a fair valuation based on a business’ metrics, results, history, team, and other factors, rather than squeezing out the last dollar.

– Presenting realistic numbers is better than presenting spreadsheet projections that don’t make sense. Investors would rather see a credible number than an outsized revenue projection.

– Units matter more than revenue. Having credibility with customers and executing against your commitments matters, because it’s not just one transactional event.

– Investors want to be convinced that they’re investing in a team, not just one person. So showcase the team and let them present and answer questions during diligence.

– Diligence for later-stage investments involves talking to customers and getting conviction from them about whether they will do what the company says they will. Procuring customer references through videos or visits is a scalable solution here.

 

Role of Corporates in Start Up Innovation Landscape

role of corporations in the robotics investment landscape

– Corporates can provide access to markets and distribution networks, and build trust in early-stage companies by putting their weight behind their product and brand. However, startups must clear high risk and benefits bars during the evaluation process to land a potential partnership.

– FOMO does not necessarily enter into the equation, but if there’s a deadline to meet, the team will try to meet it as fast as possible.

– Large corporates have integration teams responsible for combining new technology into the company after mergers or acquisitions, while smaller companies may assign temporary teams for this task.

– To maintain relationships with corporates through different team members and priorities, early-stage companies should focus on key advocates and sponsors while also branching out to other stakeholders within different teams and functions.

– Corporate venture capital investments can offer access to expertise that would otherwise be costly, and accelerate regulatory timelines.

– Manufacturing experts from large corporates can help reduce costs by renegotiating contracts, playing hard ball with suppliers, and identifying alternatives.

 

Exiting a Robotics Business

exit strategy robotics

– When it comes to exit strategy for startups, good communication channels are key in keeping options open. Founders should be proactive and keep everyone updated quarterly.

– Opinions are mixed on strategic investors. If you get the right partner, it gives your business model some validation. However, you want to limit your involvement with strategics if you have lots of options, as you don’t want to be limited to a single acquirer. Bottom line: either have multiple strategics on your cap table, or zero.

– The lifecycle of a robotics company can be up to 20 years, so plan for the long game.

– Personal relationships between board members and CEOs are more important than anything right now. A good board will have consistent and easy-to-pitch messaging for potential investors.

– The use of robotics is a long term secular trend that will not stop, and is accelerating with broader adoption and understanding of AI and machine learning.

 

To stay in touch, follow Robotics invest on LinkedIn and Twitter

Albert Invent’s $7.5M Seed Round

Modernizing the chemical R&D tech stack

We’re excited to partner on Albert Invent’s $7.5M Seed round!

You’d be surprised how much pen-and-paper is still used in chemical R&D labs nowadays.

The current state of the market involves:
– Low levels of digitization (Excel + paper notebooks)
– Unintegrated tools and machines
– Experiment data loss, leading to repeat experimentation
– No ability to search and share cross-functionally

The solution: 
Albert, which lets R&D teams track chemistry data

Why Albert?
– Co-founders Nick Talken and Ken Kisner have roots in Henkel, a giant in the chemicals industry, which they joined after it acquired their 3D photopolymers manufacturing startup, Molecule, in 2019. Ken grew up in a paint factory and, as he put it to us, has “paint running through his veins”
– Albert’s product is now used by multibillion dollar corporations across multiple regions

Why We Invested in Carrot Fertility: A global leader in fertility healthcare and family-forming

Women are half of the world’s population and 80 percent of healthcare consumers, yet efforts to fund women’s health have been marginalized time and time again. In recent years, growing recognition by industry decision-makers has emerged on the varied health challenges faced by women, including increasing demand for fertility services.

While women’s health encompasses vastly more than fertility-related events, the fertility market is much larger than what many people recognize. A recent report from the World Health Organization states around 17.5% of the adult population – one in six people worldwide – experience infertility. The data shows that the market is large and growing. According to the CDC, there were nearly 370,000 assisted reproductive technology (ART) cycles completed in the U.S. in 2021, a 19% increase from 2020.

Enter Carrot Fertility, the leading global fertility care platform enabling employers to offer a highly flexible benefit to support employees in the “pursuit of parenthood” through financial support, care navigation, and provider access.

Tremendous Unmet Need: Traditional healthcare benefits often do not cover family-building.

The fertility and family-building benefits market is accelerating because of favorable demographic and economic trends. Families are having children later in life than they did previously, driving increased interest in solutions for both men and women as they face the prospect of declining fertility. As a result, male and female preservation via freezing of sperm and eggs, respectively, has expanded rapidly.

Further, fertility providers no longer focus exclusively on a narrow demographic, broadening services to be more inclusive of diverse populations. For example, LGBTQ couples are increasingly forming families in ways that benefit from fertility support via surrogacy, assisted reproductive technology, and adoption services.

Tight competition to attract and retain talent at companies is also increasing driving greater attention to these needs, with more family-friendly benefits high on employers’ priority lists. The net result is a more inclusive range of services for everyone who faces fertility-related challenges.

A More Inclusive Solution: Carrot makes family-forming benefits accessible to all.

Many companies focus on spreading their benefits dollars widely, considering women’s health to be a general category alongside mental health, musculoskeletal care, diabetes care, and related “verticals.” The problem with this approach is that it conflates gender with conditions, whereas women’s needs are far more diverse, specific, and complex than can be served with a “women’s health” offering.

Carrot saw an opportunity to develop a compelling solution to a specific problem – fertility – and make it accessible for all, wherever those audiences may be in their fertility and family-forming journey. Fertility care is complicated, and connecting patients with providers and optimal care is just one piece to support them through many of the most meaningful moments of their lives.

“Patients are often left to make care decisions based on limited knowledge, which can lead to unnecessary treatments and poorer care experiences and outcomes. We saw a valuable, important opportunity to provide more women with both connections to care and educational resources to accompany care in order to allow them to make more informed choices.”

-Tammy Sun, CEO, Carrot Fertility

Carrot offers a more inclusive and exhaustive fertility-related benefit that covers all components of and paths to family formation.

  • -Curated Care: Carrot’s substantive network of highly vetted providers enables patients to navigate care options based on their individual needs rather than a predefined, one-size-fits-all course of treatments – all backed by the support of an experienced clinical team.
  • -Cost Savings: Carrot’s financial model enables an employer-specific contribution, rather than a limited benefit for specific surgeries (e.g., IVF), which provides companies with greater flexibility in their benefits offering while adhering to budgets. This allows Carrot to sit alongside patients to advise them about how to make the best use of each employer’s benefits offering.
  • -Global Coverage: By offering benefits on a global basis, Carrot appeals to many buyers of these services who want to offer similar benefits to all employees regardless of their country of residence.
  • -Every Person, Every Journey: Carrot offers evidence-based support for every fertility journey — fertility education, egg and sperm freezing, in vitro fertilization (IVF), pregnancy and postpartum support, gestational surrogacy, adoption, menopause, low testosterone, and more.

Carrot’s platform and wraparound services are already making an impact; quality data released in January 2023 show that Carrot customers had the highest reported single embryo transfer (SET) rate among fertility benefits vendors as well as an IVF pregnancy rate greatly exceeding national averages.

Read why leading companies across industries chose Carrot’s inclusive fertility healthcare and family-forming support for their employees.

A Dynamic Duo: Founding team brings technology and clinical expertise.

Achieving “product-market fit” – or alignment of a product’s value proposition to an underserved market need – is critical to any startup’s success. Carrot Fertility’s two female co-founders, Tammy Sun and Dr. Asima Ahmad, MD, MPH, bring different yet essential competencies to the challenge of building a better fertility offering.

Prior to the founding of Carrot, Sun was head of partnerships at Evernote and personally experienced the limits of existing fertility offerings. In an MSNBC feature, she shared that at a doctor’s appointment, she found out she had “premature ovarian failure,” which meant that her ovaries were essentially getting older significantly faster than her biological age would imply — and that she would go through early onset menopause. Her co-founder, Dr. Ahmad, brought to Carrot her expertise as a clinical leader in infertility with a thriving medical practice as a reproductive endocrinology and infertility specialist at Fertility Centers of Illinois.

“When we met Tammy and Asima, we found a talented team with a compelling vision and business model for addressing a key gap in the industry faced by many patients and employers.”

-Carl Byers, Partner, F-Prime Capital

Future of Digital Health: F-Prime’s commitment to driving innovation.

Carrot’s mission to provide fertility care for all and its dedicated co-founders made F-Prime’s decision to invest in the company a straightforward one. In August 2020, we were delighted to invest in Carrot Fertility’s $24 million Series B funding alongside U.S. Venture Partners and existing investors including CRV, Precursor Ventures, Maven Ventures, and Uncork Capital. Later, we welcomed Orbimed and Tiger Global to the ongoing effort to enable success for Carrot and all of its stakeholders.

Like Carrot, our team and portfolio companies aim to reshape the healthcare system to address pressing challenges and enable everyone to access the care they need.

Subscribe to our newsletter to get the latest updates on how our portfolio companies continue to lead the way in their respective fields.

Announcing the Travel Tech Titans: Celebrating the Game-Changing Innovators in Travel

Today, we are thrilled to announce the winners of the inaugural Travel Tech Titans, our way of celebrating the game-changing innovators in travel.

Travel is a keystone industry, representing 10% of global GDP before the pandemic. A small number of dominant giants have long controlled the B2B infrastructure behind travel. The first wave of companies — including Amadeus, Sabre and Oracle — laid the foundation for today’s travel infrastructure. The second wave of innovation brought the industry online and led to significant B2C businesses emerging: Expedia, Booking.com, and even Airbnb. Decades have passed and these Goliaths are firmly entrenched, having weaved an intricate web of multi-decade customer and partner relationships. Today, these dominant players have a combined market value exceeding $150 billion.

core trends in travel tech

However, the industry is now facing new and unprecedented challenges: staff shortages, rising customer expectations, transition to carbon neutral, GenZ’s distinct travel tastes, and big tech trying to enter the distribution game. We believe that startups in the industry have a unique position to help solve these challenges. The pandemic ripped the Band-Aid off the industry’s aging infrastructure and exposed the need for rapid tech innovation and modern customer experiences.

With the tide now turning, we believe it’s crucial to acknowledge and celebrate the startups that are doing amazing work in this industry. These companies are the driving force behind the transformation of travel, and we anticipate that many of them will become the pillars of the industry in the future. With this ambition in mind, we are thrilled to present the inaugural Travel Tech Titans award, an initiative that recognizes and honors these startups’ exceptional contributions to the industry’s future.

Almost 200 nominees represent an impressive cross-section of the travel tech industry, with headquarters in 21 countries and more than 12,000 employees, demonstrating the global nature of the industry. Ranging from bootstrapped to pre-IPO, nominees have cumulatively raised $6.9 billion since founding, and raised 128 funding rounds in the past 18 months alone. In a world where the VC market has slowed, that is an astounding recognition of the tailwinds and interest in travel tech. Interestingly, 70% of the nominated companies are focused on infrastructure and data, addressing the longstanding systemic backend issues in travel.

The Travel Tech Titans’ exceptional judges had the difficult job of diligently studying the ~200 nominees to select the most exciting and impactful companies within the group. We’re pleased to share the winners today:

 

Early stage winners have raised 0-$10M in funding.

  • BTP AutomationAggregates and analyzes corporate travel hotel data from multiple sources, providing real-time visibility on hotel spend plus an end-to-end and automated RFP.
  • Deal EngineAutomates manual processes currently done by armies of people in the travel industry.
  • Grapevine: First-to-market AI technology that identifies missed retailing opportunities from data and optimizes revenue through intelligent, post-booking remarketing.
  • NeoKe: A self-sovereign identity platform enhancing travel experiences like check-ins and border control by streamlining personal data management, prioritizing privacy, and enabling seamless interactions.
  • NLX: Delivers world-class conversational AI-powered customer experiences that meet the scale, complexity, and compliance standards of enterprise organizations.
  • Thrust Carbon: Analyses multiple data points to provide carbon calculations across the entire travel spectrum, using the ICAO methodology to layer both aircraft model and class into the calculations.

 

mid stage travel tech titans

Mid-stage winners have raised $10-$50M in funding.

  • Amenitiz: An easy-to-use, all-in-one hotel management software for independent hoteliers, bed-and-breakfast owners, and apartment owners.
  • Canary Technologies: Modernizing the hotel tech stack with its award-winning end-to-end guest management system and digital authorizations solutions.
  • Fora: A new kind of travel agency, with a modern, tech-forward, and inclusive approach built for the next generation of travel advisors, who can earn flexible income booking trips.
  • point.me: The world’s first real time search engine for flights booked using airline miles and credit card rewards points.
  • Sensible Weather: A climate risk technology company that aims to change the way people interact with the weather by making the unpredictable predictable, and creating products and experiences that ease stress.
  • Sherpa: APIs and widgets that allow airlines and other travel companies to make border crossings a seamless experience.

 

late stage travel tech titans

Late-stage winners have raised $50M+ in funding.

  • Cloudbeds: Helps independent properties increase revenue, streamline operations, and delight guests through a single unified system.
  • Hopper: A travel app that uses predictive analytics to make travel recommendations.
  • Mews: Building the industry’s new standard operating system for properties and services.
  • OTA Insight: Empowers hoteliers to deliver smarter revenue, distribution, and marketing outcomes through a market-leading commercial platform.
  • Selfbook: Works in tandem with hotels’ existing technology systems to enhance direct conversion, revenue, cash flow control, and security.
  • TravelPerk: A platform for SMBs to easily book, manage, and report on business travel, with an industry-leading inventory and ability to help businesses scale on budget.

Please join us in celebrating the winners of the Travel Tech Titans awards, showcasing their remarkable accomplishments and their role as game-changers in the travel tech space. Together, we are forging a brighter future for travel and hospitality.

 

Written in collaboration with Lucile Cornet at Eight Roads Ventures Europe.

A Bet on Vertical Robotics

Defining new frontier in frontier tech

The robotics industry is growing fast, with tremendous growth in terms of funding and number of companies over the last five years. Between 2018 and 2022, total funding in the space grew $7B to $18.6B, spiking to $28B in 2021. Once heavily focused on autonomous vehicles, the robotics industry’s profile is now changing to reflect an increased interest in companies developing solutions for specific vertical use cases.

In the midst of a broader pullback in tech funding (for example, AV investment dropped almost 60 percent to $4.1 billion last year) F-Prime Capital’s recent State of Robotics report found that funding for “vertical robotics” companies actually grew in 2022. That increase — to $6.9 billion from $6 billion in 2021 — was driven by companies building vertical robotics for the logistics, defense and security, medical, and manufacturing sectors. The agriculture, lab and pharma, food, and construction and mining categories have also seen increased investor interest.

Ahead of our upcoming Robotics Invest summit (Wednesday, June 7 in Boston), I joined my fellow organizer and robotics investor Fady Saad of Cybernetix Ventures to answer some questions about the definition of vertical robotics, why it’s different from other sectors in the industry, and how the right teams will find success.

 

How would you define vertical robotics?

Sanjay Aggarwal: Vertical robotics target mostly industrial use cases with end-to-end solutions.  Typically, companies building vertical robotics augment tasks which are otherwise performed by humans, thereby enhancing the productivity of existing labor.

Fady Saad: We see vertical robotics targeting the logistics, construction, and healthcare sectors, among others. An example might be a logistics robot that focuses loading and unloading trucks, or on pick-and-place use cases. These products will be focused on specific use cases within a vertical, and might have specific business models and/or deployment and operational processes.

 

Why do you find the category interesting, and why now? 

Fady: This classification is interesting because it gives innovators, investors, service providers, and customers a specific focus and alignment, as they’re looking at more or less the same landscapes and speaking the same languages and terminologies. The robotics industry has been suffering from the challenge of having technologies seeking markets, an approach that wasted a lot of time and money. Having these vertically focused approaches could significantly expedite the search for product-market fit. The acquisition of Kiva in 2012 by Amazon was the most significant example of a market-driven innovation, and the success of 6 River, Locus, Motional, Auris, and many others was another validation of the approach.

Sanjay: Successful vertical robotics companies deliver solutions that reliably and predictably provide strong ROI to customers, in the form of higher throughput and more accuracy. Given the strong focus on specific use cases, vertical robotics companies are able to deeply understand both the existing processes and customer pain points, leading to fit-for-purpose solutions that deliver ROI. The last couple of years has seen a significant increase in vertical robotics companies as market tailwinds intensify, and as entrepreneurs shift their focus away from the AV sector.

 

Which subsectors within the vertical robotics category do you find most appealing for investment?

Sanjay: Logistics has been the workhorse industry for vertical robotics, with numerous large companies across that sector. However, most of the logistics use cases today have fairly strong incumbent robotics providers. Similarly, manufacturing was one of the earliest adopters of robotics, though newer solutions face a high bar in proving they are superior to existing offerings. One of the largest untapped opportunities is robotics for outdoor use cases, including agriculture, construction, and mining. These industries are experiencing strong tailwinds of growth and are seeing numerous labor challenges — a combination that drives the need for innovative robotics solutions.

Fady: At Cybernetix Ventures, we developed our investment thesis based on quantitative and qualitative analysis of the robotics industry over the last 12 years and more than 10 verticals that we have been interacting with in different capacities. Based on that analysis, we believe that four key verticals will generate significant returns in the coming five to 10 years. These are advanced manufacturing, logistics and warehousing, architecture, engineering and construction, and healthcare — which includes lab automation, medical devices, surgical robots, and more. Beyond this timeframe, we are monitoring interesting developments in outdoor and indoor agriculture; oil, gas, and mining, and food preparation.

 

What are the key factors for success for any vertical robotics team? 

Fady: Deep knowledge of how their target vertical is structured, organized, and operated. What are the value and supply chains in this particular vertical? What are the most common business and pricing models? Who makes or influences the decisions? What factors is this particular vertical most sensitive to?

Sanjay: While any robotics team requires depth of technical expertise, the companies that stand out are those which also have deep domain expertise. The domain expertise enables those companies to quickly identify high-value, yet feasible use cases to target and navigate the go-to-market nuances of their targeted industry.

 

How does robotics investment differ from other categories across the broader tech industry? 

Sanjay: The lifecycle of a robotics business is very different from a software business.  Progress in the early stages of a robotics business can sometimes feel slow and require more capital than a software business. Interfacing with the real world means solutions take more time to perfect, and customers are risk averse so they may have an extended validation period to prove ROI and adapt their processes.

However, if you can cross those hurdles, customers will often drive very rapid adoption, which can create a hockey-stick growth curve. All of this also means that robotics has inherently higher competitive moats, and customers are very sticky once they’ve decided to scale.

Fady: Cybernetix Ventures was formed with the belief that robotics investment is different — and one can even claim that it’s a whole investment class in itself. The financial models, milestones, required capital, revenue structure and market dynamics, supply chain, manufacturing and support structures, and even portfolio support models are different.

Therefore, we decided to take the initiative and plan a first-of-its-kind event around making successful investments in robotics, called Robotics Invest. We are excited to have F-Prime as a key co-organizer together with an amazing group of underwriters and supporters. In this event, we’ve curated some of the most successful entrepreneurs and investors in the space to collectively share the most effective ways to build and invest in robotics.

 

Robotics Invest is an invite-only summit packed with keynotes, panels, case studies, and more on Wednesday, June 7 in Boston. You can request your invite here

There Are Gaps In The US Real-Time Payment System. Who Will Fill Them?

A lot of ink has been spilled speculating about FedNow, the US government’s forthcoming real-time payments infrastructure — especially how and why it differs from The Clearing House’s RTP product, same-day ACH, and Visa Direct.

However, as Rocio Wu points out in her regular column for Forbes, few have considered whether businesses and consumers in the US will actually adopt RTP payments on the back of FedNow. In this story, she compares the American payments landscape with the rest of the world, much of which has already rolled out and adopted their own government RTP infrastructure, to see what lessons can be learned.

Read the full story here.

Originally published in Forbes

Robotics – Has the Time Finally Arrived for Venture Capital?

Did you ever watch the original Lost in Space series from 1965?

The last 50 years of sci-fi television and movies have led many of us to expect that robots are an inevitable part of our future. To be sure, robots are now pervasive in some industries, particularly manufacturing. However, they are far from being a part of our daily lives, and the character “Robot” (of Lost in Space) still feels like a distant dream.

Nevertheless, the last few years have felt different. Autonomous vehicles are moving from research labs to the roadBoston Dynamics releases jaw-dropping new videos every few months, and (a few) venture capitalists are starting to take notice.

 

What’s really going on?

As one of the VCs that have actively invested in robotics the last few years, we’ve seen a rapidly changing landscape of ‘hot sectors’, business model evolution, and investment and exit dynamics. At the same time, it’s been difficult to get a grasp on exactly what’s going on. Robotics as a sector is not well-defined in the standard deal databases that VCs use, making it difficult to get a comprehensive overview.

To remedy the situation, we spent the last several months doing a comprehensive analysis of more than 1,250 robotics companies that have raised capital in the last five years, with a company-by-company analysis of which companies should be classified as ‘robotics’ and, if so, what use case they are pursuing. You can access the full report here.

 

Where are the VC dollars going?

The last five years saw $90B invested in startups across the global robotics industry, representing roughly 10 percent of overall VC investments in technology. As with the rest of the market, there was a significant spike of investment in 2021, though the market remained robust into 2022, with dollars invested exceeding 2020 highs. Western markets, including the US, Europe, and Israel, were 70 percent of overall investment, though Asia — particularly China — is becoming a growing force.

Across the Western markets, we identified three primary categories of robotics investments: Autonomous Vehicles (public roads only), Vertical Robotics (use-case specific and mostly industrial-focused – more on that below) and Enabling Systems (hardware and software components for developing a complete solution). Not surprisingly, the major driver of investment has been for AV companies, with more than 50 percent of investments flowing to AV in most years. However, with the sharp pull back of investments in 2022, AV was particularly impacted as investors began to question the path to commercialization for many of these companies.

While not a focus of our research, we expect Asia and China to play an increased role in the robotics industry. First, significant investment in technology in the region means that most sensors, robotic arms, and electronic components used in robotics will continue to be sourced from China. Furthermore, many companies in robotics — and particularly AV — are doing significant R&D work from China. Second, as robotics companies scale, China will continue to play an important role in the supply chain. While geo-political forces may change this role over time, the near-term alternatives are limited.

As an end-user market, Asia has also been an early adopter of robotics. For example, we’ve seen many companies focused on logistics robotics find success selling in Japan. Meanwhile, several Chinese automotive OEMs are already rolling out LiDar on production vehicles, while western OEMs are stuck in the planning phases. At the same time (perhaps as a reaction to geo-political tension) China is becoming a distinct ecosystem of its own for robotics. Across several use cases such as logistics, mining, and agriculture, there are a unique set of China-based players which primarily serve the local market.

 

You’ve heard about Vertical SaaS…what about Vertical Robotics?

One of the more exciting trends in the industry has been the growth of Vertical Robotics, with the sector seeing significant growth in 2021 and defying the overall VC market by growing again in 2022. Vertical Robotics focuses on very specific use cases across a range of industries, including logistics, medicine, defense, and manufacturing.

Vertical Robotics is interesting for many reasons. First, companies can focus on very specific use cases within industries, bounding the problem statement to make it more suitable for robotics. Second, entrepreneurs can leverage deep domain expertise to better understand customer pain points and develop more effective go-to-market strategies. Finally, macro tailwinds of escalating labor costs and labor shortages across industries create strong willingness for customer adoption.

At the same time, Vertical Robotics is still in its infancy. Most dollars invested to-date are in early- stage deals, and other than in a few industries, the success stories are still to be told. Some areas, such as logistics, medical, and defense, have seen a disproportionate share of dollars invested and exited. Others, such as construction, mining, and agriculture, are still in the early stages of company formation and development of scalable businesses.

 

Is anyone making money?

The critical sign of sustainability of any area of venture are whether dollars invested are yielding multi-fold increases in dollars exited. On this measure, while signs are positive, there is work to do. From a valuation perspective, there have been 38 robotics unicorns over the last five years. Of those, 14 had public offerings, five were acquired, one shut down (Argo), and 18 are still private.

On the public side, many companies took advantage of the SPAC frenzy in 2021, though today only three still trade above $1B market cap, and the aggregate market cap of VC-backed robotics companies which went public is only $20B. M&A has generally been more productive, with $20B of overall exit value, though it is highly skewed toward the five unicorns which were acquired. Of the 18 companies that are still private, last round valuations sum to more than $100B, though some may ultimately struggle to justify their valuations.

In total, of the $60B or so invested in western markets over the last five years, there is $140B of realized and unrealized exit value, plus upside from the earlier stage companies that are still maturing.  Considering that investors own only a fraction of a company at exit, one would ideally see a multiple of at least 4-5x exit value compared to invested dollars, and as more companies mature, hopefully we will get there.

The more important exit trend for robotics may be the reversion to valuation based on business fundamentals, rather than hype. AV arguably fell into the latter camp, but Vertical Robotics feels much more like the former. Many public robotics companies trade at valuation multiples that rival those of the best SaaS companies, and a similar trend can be seen in some recent private funding rounds. In the long term, robotics exits will be driven by those companies that demonstrate the ability to scale commercially.

 

But hardware is hard, isn’t it?

One area of conventional VC wisdom has curtailed robotics investing: ‘never invest in hardware.’ Hardware businesses are too costly to build, product cycles are too long, and eventually they are susceptible to commoditization.

While these things continue to be true to an extent, the market is rapidly changing. Most robotics startups today rely primarily on off-the-shelf hardware, with the innovation focused on how they leverage modern advances in computer vision and machine learning. Moreover, rapid prototyping enabled by 3D printing helps create faster iteration cycles. This combination helps shorten product development times and reduce costs. At the same time, the equipment financing market is starting to warm up to venture-backed robotics companies, helping to mitigate capital requirements for production build-outs. Finally, entrepreneurs are getting more savvy about identifying use cases where robotics can deliver rapid time-to-value, and which don’t require multi-year science projects to solve.

Robotics businesses will always be ‘harder’ than building software businesses — but that also means they have a much stronger moat. Many companies have few truly direct competitors, especially when you look at Vertical Robotics start-ups. Even businesses that look similar on the surface are often solving very different use cases once you dig a layer deeper.

 

Danger, Will Robinson?

Investment in AV was a catalyst for a new generation of entrepreneurs and engineers to cut their teeth in robotics, and they are now leveraging that know-how to build startups that solve real customer pain points. It is true that many investors will look at the data on robotics and remain unconvinced — for them, there are too few successful exits, not enough high dollar-paying acquirers, and hardware businesses are still too hard. But the direction of travel and growing set of opportunities is unmistakable. Robotics is still in its early days as a focus sector for VCs, but the sheer breadth of activity, quality of entrepreneurs, and emergence of market leaders is starting to create a virtuous cycle.

We at F-Prime are extremely bullish about the opportunity, and we urge you to join the ride!